leadf
logo-loader
viewCytoDyn Inc.

Full interview: CytoDyn offers update on leronlimab following encouraging results on breast cancer trial

CytoDyn Inc. (OTCQB:CYDY) CEO Nader Pourhassan and IncellDx Inc CEO Dr Bruce Patterson offer an update on leronlimab's mechanism of action (MOA) in regards to its ongoing cancer trials, specifically in metastatic breast cancer. Dr Patterson says the amazing thing about CCR5 is how it plays multiple roles in tumor invasion and metastasis. He reveals why the Vancouver-based company is seeing such encouraging results

Quick facts: CytoDyn Inc.

Price: 3.3565 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $1.91 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

CytoDyn addresses WSJ & SeekingAlpha articles, calls on investors to pay...

CytoDyn Inc. (OTCQB:CYDY) CEO Nader Pourhassan addresses the recent articles published by the Wall Street Journal and SeekingAlpha, in regards to its participation in Operation Warp Speed. Pourhassan says shareholders should pay attention to the group's fundamentals, adding to 'only buy the...

4 weeks, 1 day ago

2 min read